Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus GRISEOFULVIN ULTRAMICROSIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus GRISEOFULVIN ULTRAMICROSIZE.
FULVICIN P/G 330 vs GRISEOFULVIN, ULTRAMICROSIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
330 mg orally once daily with fatty meal to enhance absorption.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
9-24 hours (mean 15 hours); prolonged in liver disease.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Category C
Category D/X
Antifungal
Antifungal